Thymoquinone alleviates liver fibrosis via miR-30a-mediated epithelial-mesenchymal transition.
Snai1
hepatic stellate cell
liver fibrosis
miR‐30a
thymoquinone
Journal
Journal of cellular physiology
ISSN: 1097-4652
Titre abrégé: J Cell Physiol
Pays: United States
ID NLM: 0050222
Informations de publication
Date de publication:
08 Oct 2020
08 Oct 2020
Historique:
received:
25
05
2020
revised:
31
08
2020
accepted:
25
09
2020
entrez:
22
10
2020
pubmed:
23
10
2020
medline:
23
10
2020
Statut:
aheadofprint
Résumé
Thymoquinone (TQ), the main active constituent of Nigella sativa seeds, has been shown to play a role in antioxidation, anti-inflammation, and antitumor. Recent studies have demonstrated that TQ contributes to the suppression of liver fibrosis. Abnormal activated epithelial-mesenchymal transition (EMT) promotes the activation of hepatic stellate cells (HSCs). However, whether the antifibrotic effects of TQ occur through inhibiting EMT is largely unknown. In this study, it was found that TQ ameliorated liver fibrosis and collagen accumulation in carbon tetrachloride (CCl
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Natural Science Foundation of China
ID : 81774109
Organisme : National Natural Science Foundation of China
ID : 81873576
Organisme : National Natural Science Foundation of China
ID : 81973620
Organisme : Medical Health Science and Technology Project of Zhejiang Provincial Health Commission
ID : 2020RC081
Organisme : Project of Wenzhou Medical University Basic Scientific Research
Organisme : Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of Zhejiang Province
ID : G2020002
Organisme : Wenzhou Municipal Science and Technology Bureau
ID : Y20190076
Organisme : Wenzhou Municipal Science and Technology Bureau
ID : ZY2019015
Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Abdelghany, A. H., BaSalamah, M. A., Idris, S., Ahmad, J., & Refaat, B. (2016). The fibrolytic potentials of vitamin D and thymoquinone remedial therapies: Insights from liver fibrosis established by CCl4 in rats. Journal of Translational Medicine, 14(1), 281. https://doi.org/10.1186/s12967-016-1040-4
Asgharzadeh, F., Bargi, R., Beheshti, F., Hosseini, M., Farzadnia, M., & Khazaei, M. (2017). Thymoquinone restores liver fibrosis and improves oxidative stress status in a lipopolysaccharide‐induced inflammation model in rats. Avicenna Journal of Phytomedicine, 7(6), 502–510.
Bai, T., Lian, L. H., Wu, Y. L., Wan, Y., & Nan, J. X. (2013). Thymoquinone attenuates liver fibrosis via PI3K and TLR4 signaling pathways in activated hepatic stellate cells. International Immunopharmacology, 15(2), 275–281. https://doi.org/10.1016/j.intimp.2012.12.020
Bai, T., Yang, Y., Wu, Y. L., Jiang, S., Lee, J. J., Lian, L. H., & Nan, J. X. (2014). Thymoquinone alleviates thioacetamide‐induced hepatic fibrosis and inflammation by activating LKB1‐AMPK signaling pathway in mice. International Immunopharmacology, 19(2), 351–357. https://doi.org/10.1016/j.intimp.2014.02.006
Bartel, D. P. (2004). MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell, 116(2), 281–297. https://doi.org/10.1016/s0092-8674(04)00045-5
Bottcher, K., & Pinzani, M. (2017). Pathophysiology of liver fibrosis and the methodological barriers to the development of anti‐fibrogenic agents. Advanced Drug Delivery Reviews, 121, 3–8. https://doi.org/10.1016/j.addr.2017.05.016
Braun, J., Hoang‐Vu, C., Dralle, H., & Huttelmaier, S. (2010). Downregulation of microRNAs directs the EMT and invasive potential of anaplastic thyroid carcinomas. Oncogene, 29(29), 4237–4244. https://doi.org/10.1038/onc.2010.169
Chang, W., Yang, M., Song, L., Shen, K., Wang, H., Gao, X., Li, M., Niu, W., & Qin, X. (2014). Isolation and culture of hepatic stellate cells from mouse liver. Acta Biochim Biophys Sin (Shanghai), 46(4), 291–298. https://doi.org/10.1093/abbs/gmt143
Choi, S. S., Syn, W. K., Karaca, G. F., Omenetti, A., Moylan, C. A., Witek, R. P., Agboola, K. M., Jung, Y., Michelotti, G. A., & Diehl, A. M. (2010). Leptin promotes the myofibroblastic phenotype in hepatic stellate cells by activating the hedgehog pathway. Journal of Biological Chemistry, 285(47), 36551–36560. https://doi.org/10.1074/jbc.M110.168542
Darakhshan, S., Bidmeshki Pour, A., Hosseinzadeh Colagar, A., & Sisakhtnezhad, S. (2015). Thymoquinone and its therapeutic potentials. Pharmacological Research, 95‐96, 138–158. https://doi.org/10.1016/j.phrs.2015.03.011
Duisters, R. F., Tijsen, A. J., Schroen, B., Leenders, J. J., Lentink, V., van derMade, I., Herias, V., van Leeuwen, R. E., Schellings, M. W., Barenbrug, P., Maessen, J. G., Heymans, S., Pinto, Y. M., & Creemers, E. E. (2009). miR‐133 and miR‐30 regulate connective tissue growth factor: Implications for a role of microRNAs in myocardial matrix remodeling. Circulation Research, 104(2), 170–178. https://doi.org/10.1161/CIRCRESAHA.108.182535
Filipowicz, W., Bhattacharyya, S. N., & Sonenberg, N. (2008). Mechanisms of post‐transcriptional regulation by microRNAs: Are the answers in sight? Nature Reviews Genetics, 9(2), 102–114. https://doi.org/10.1038/nrg2290
Ghazwani, M., Zhang, Y., Gao, X., Fan, J., Li, J., & Li, S. (2014). Anti‐fibrotic effect of thymoquinone on hepatic stellate cells. Phytomedicine, 21(3), 254–260. https://doi.org/10.1016/j.phymed.2013.09.014
Hosseinian, S., Shahraki, S., Ebrahimzadeh Bideskan, A., Shafei, M. N., Sadeghnia, H. R., Soukhtanloo, M., Rahmani, F., & Khajavi Rad, A. (2019). Thymoquinone alleviates renal interstitial fibrosis and kidney dysfunction in rats with unilateral ureteral obstruction. Phytotherapy Research, 33(8), 2023–2033. https://doi.org/10.1002/ptr.6376
Jin, Y., Wang, J., Han, J., Luo, D., & Sun, Z. (2017). MiR‐122 inhibits epithelial‐mesenchymal transition in hepatocellular carcinoma by targeting Snail1 and Snail2 and suppressing WNT/beta‐cadherin signaling pathway. Experimental Cell Research, 360(2), 210–217. https://doi.org/10.1016/j.yexcr.2017.09.010
Khader, M., Bresgen, N., & Eckl, P. M. (2009). In vitro toxicological properties of thymoquinone. Food and Chemical Toxicology, 47(1), 129–133. https://doi.org/10.1016/j.fct.2008.10.019
Khan, M. A. (1999). Chemical composition and medicinal properties of Nigella sativa Linn. Inflammopharmacology, 7(1), 15–35. https://doi.org/10.1007/s10787-999-0023-y
Lee, K., & Nelson, C. M. (2012). New insights into the regulation of epithelial‐mesenchymal transition and tissue fibrosis. International Review of Cell and Molecular Biology, 294, 171–221. https://doi.org/10.1016/B978-0-12-394305-7.00004-5
Li, J., Khan, M., Wei, C., Cheng, J., Chen, H., Yang, L., Ijaz, I., & Fu, J. (2017). Thymoquinone inhibits the migration and invasive characteristics of cervical cancer cells SiHa and CaSki in vitro by targeting epithelial to mesenchymal transition associated transcription factors Twist1 and Zeb1. Molecules, 22(12), 2105. https://doi.org/10.3390/molecules22122105
Liu, Z., Long, J., Du, R., Ge, C., Guo, K., & Xu, Y. (2016). miR‐204 regulates the EMT by targeting snai1 to suppress the invasion and migration of gastric cancer. Tumour Biology, 37(6), 8327–8335. https://doi.org/10.1007/s13277-015-4627-0
Ma, S., Jia, W., & Ni, S. (2018). miR‐199a‐5p inhibits the progression of papillary thyroid carcinoma by targeting SNAI1. Biochemical and Biophysical Research Communications, 497(1), 181–186. https://doi.org/10.1016/j.bbrc.2018.02.051
Ma, T., Zhao, Y., Lu, Q., Lu, Y., Liu, Z., Xue, T., & Shao, Y. (2018). MicroRNA‐30c functions as a tumor suppressor via targeting SNAI1 in esophageal squamous cell carcinoma. Biomedicine and Pharmacotherapy, 98, 680–686. https://doi.org/10.1016/j.biopha.2017.12.095
Mostofa, A. G. M., Hossain, M. K., Basak, D., & Bin Sayeed, M. S. (2017). Thymoquinone as a potential adjuvant therapy for cancer treatment: Evidence from preclinical studies. Frontiers in Pharmacology, 8, 295. https://doi.org/10.3389/fphar.2017.00295
Muraoka, N., Yamakawa, H., Miyamoto, K., Sadahiro, T., Umei, T., Isomi, M., Nakashima, H., Akiyama, M., Wada, R., Inagawa, K., Nishiyama, T., Kaneda, R., Fukuda, T., Takeda, S., Tohyama, S., Hashimoto, H., Kawamura, Y., Goshima, N., Aeba, R., … Ieda, M. (2014). MiR‐133 promotes cardiac reprogramming by directly repressing Snai1 and silencing fibroblast signatures. EMBO Journal, 33(14), 1565–1581. https://doi.org/10.15252/embj.201387605
Nordin, A., Kamal, H., Yazid, M. D., Saim, A., & Idrus, R. (2019). Effect of Nigella sativa and its bioactive compound on type 2 epithelial to mesenchymal transition: A systematic review. BMC Complementary and Alternative Medicine, 19(1), 290. https://doi.org/10.1186/s12906-019-2706-2
Ohkubo, T., & Ozawa, M. (2004). The transcription factor Snail downregulates the tight junction components independently of E‐cadherin downregulation. Journal of Cell Science, 117(Pt 9), 1675–1685. https://doi.org/10.1242/jcs.01004
Ouzounova, M., Vuong, T., Ancey, P. B., Ferrand, M., Durand, G., Le‐Calvez Kelm, F., Croce, C., Matar, C., Herceg, Z., & Hernandez‐Vargas, H. (2013). MicroRNA miR‐30 family regulates non‐attachment growth of breast cancer cells. BMC Genomics, 14, 139. https://doi.org/10.1186/1471-2164-14-139
Pourgholamhossein, F., Sharififar, F., Rasooli, R., Pourgholi, L., Nakhaeipour, F., Samareh‐Fekri, H., Iranpour, M., & Mandegary, A. (2016). Thymoquinone effectively alleviates lung fibrosis induced by paraquat herbicide through down‐regulation of pro‐fibrotic genes and inhibition of oxidative stress. Environmental Toxicology and Pharmacology, 45, 340–345. https://doi.org/10.1016/j.etap.2016.06.019
Ragheb, A., Attia, A., Eldin, W. S., Elbarbry, F., Gazarin, S., & Shoker, A. (2009). The protective effect of thymoquinone, an anti‐oxidant and anti‐inflammatory agent, against renal injury: A review. Saudi Journal of Kidney Diseases and Transplantation, 20(5), 741–752.
Schmittgen, T. D., & Livak, K. J. (2008). Analyzing real‐time PCR data by the comparative C(T) method. Nature Protocols, 3(6), 1101–1108.
Shoieb, A. M., Elgayyar, M., Dudrick, P. S., Bell, J. L., & Tithof, P. K. (2003). In vitro inhibition of growth and induction of apoptosis in cancer cell lines by thymoquinone. International Journal of Oncology, 22(1), 107–113.
Tang, Y., Tang, Y., & Cheng, Y. S. (2017). miR‐34a inhibits pancreatic cancer progression through Snail1‐mediated epithelial‐mesenchymal transition and the Notch signaling pathway. Scientific Reports, 7, 38232. https://doi.org/10.1038/srep38232
Tsuchida, T., & Friedman, S. L. (2017). Mechanisms of hepatic stellate cell activation. Nature Reviews: Gastroenterology & Hepatology, 14(7), 397–411. https://doi.org/10.1038/nrgastro.2017.38
Usami, Y., Satake, S., Nakayama, F., Matsumoto, M., Ohnuma, K., Komori, T., Semba, S., Ito, A., & Yokozaki, H. (2008). Snail‐associated epithelial‐mesenchymal transition promotes oesophageal squamous cell carcinoma motility and progression. Journal of Pathology, 215(3), 330–339. https://doi.org/10.1002/path.2365
Wang, K., Jin, W., Jin, P., Fei, X., Wang, X., & Chen, X. (2017). miR‐211‐5p suppresses metastatic behavior by targeting SNAI1 in renal cancer. Molecular Cancer Research, 15(4), 448–456. https://doi.org/10.1158/1541-7786.MCR-16-0288
Wang, T., Chen, G., Ma, X., Yang, Y., Chen, Y., Peng, Y., Bai, Z., Zhang, Z., Pei, H., & Guo, W. (2019). MiR‐30a regulates cancer cell response to chemotherapy through SNAI1/IRS1/AKT pathway. Cell Death & Disease, 10(3), 153. https://doi.org/10.1038/s41419-019-1326-6
Xu, M., Li, J., Wang, X., Meng, S., Shen, J., Wang, S., Xu, X., Xie, B., Liu, B., & Xie, L. (2018). MiR‐22 suppresses epithelial‐mesenchymal transition in bladder cancer by inhibiting Snail and MAPK1/Slug/vimentin feedback loop. Cell Death & Disease, 9(2), 209. https://doi.org/10.1038/s41419-017-0206-1
Yu, F., Chen, B., Dong, P., & Zheng, J. (2017). HOTAIR epigenetically modulates PTEN expression via MicroRNA‐29b: A novel mechanism in regulation of liver fibrosis. Molecular Therapy, 25(1), 205–217. https://doi.org/10.1016/j.ymthe.2016.10.015
Yu, F., Lu, Z., Chen, B., Wu, X., Dong, P., & Zheng, J. (2015). Salvianolic acid B‐induced microRNA‐152 inhibits liver fibrosis by attenuating DNMT1‐mediated Patched1 methylation. Journal of Cellular and Molecular Medicine, 19(11), 2617–2632. https://doi.org/10.1111/jcmm.12655
Zhang, L., Wang, Y., Li, W., Tsonis, P. A., Li, Z., Xie, L., & Huang, Y. (2017). MicroRNA‐30a regulation of epithelial‐mesenchymal transition in diabetic cataracts through targeting SNAI1. Scientific Reports, 7(1), 1117. https://doi.org/10.1038/s41598-017-01320-3
Zhang, W., Chang, H., Zhang, H., & Zhang, L. (2017). MiR‐30e attenuates isoproterenol‐induced cardiac fibrosis through suppressing Snai1/TGF‐beta signaling. Journal of Cardiovascular Pharmacology, 70(6), 362–368. https://doi.org/10.1097/FJC.0000000000000526
Zhao, W., Yin, C. Y., Jiang, J., Kong, W., Xu, H., & Zhang, H. (2019). MicroRNA‐153 suppresses cell invasion by targeting SNAI1 and predicts patient prognosis in glioma. Oncology Letters, 17(1), 1189–1195. https://doi.org/10.3892/ol.2018.9706
Zheng, J., Wang, W., Yu, F., Dong, P., Chen, B., & Zhou, M. T. (2018). MicroRNA‐30a suppresses the activation of hepatic stellate cells by inhibiting epithelial‐to‐mesenchymal transition. Cellular Physiology and Biochemistry, 46(1), 82–92. https://doi.org/10.1159/000488411
Zheng, J., Wu, C., Xu, Z., Xia, P., Dong, P., Chen, B., & Yu, F. (2015). Hepatic stellate cell is activated by microRNA‐181b via PTEN/Akt pathway. Molecular and Cellular Biochemistry, 398(1‐2), 1–9. https://doi.org/10.1007/s11010-014-2199-8
Zheng, J., Yu, F., Dong, P., Wu, L., Zhang, Y., Hu, Y., & Zheng, L. (2016). Long non‐coding RNA PVT1 activates hepatic stellate cells through competitively binding microRNA‐152. Oncotarget, 7(39), 62886–62897. https://doi.org/10.18632/oncotarget.11709
Zhou, Q., Yang, M., Lan, H., & Yu, X. (2013). miR‐30a negatively regulates TGF‐beta1‐induced epithelial‐mesenchymal transition and peritoneal fibrosis by targeting Snai1. American Journal of Pathology, 183(3), 808–819. https://doi.org/10.1016/j.ajpath.2013.05.019